Novel GLP-1 analog

JP7863526B2Active Publication Date: 2026-05-21SUN PHARMACEUTICAL INDUSTRIES LTD
View PDF 4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
SUN PHARMACEUTICAL INDUSTRIES LTD
Filing Date
2023-03-22
Publication Date
2026-05-21

AI Technical Summary

Technical Problem

Existing GLP-1 analogs have a short half-life and require frequent administration, leading to challenges in maintaining effective glucose control and weight management for diabetes treatment.

Method used

Development of a novel GLP-1 analog with an extended C-terminus, acylated with specific fatty acid groups via a linker, enhancing stability and duration of action, suitable for oral administration.

Benefits of technology

The novel GLP-1 analog demonstrates improved potency and prolonged action, reducing blood glucose levels and food intake, with potential for less frequent dosing and better patient adherence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863526000058
    Figure 0007863526000058
  • Figure 0007863526000059
    Figure 0007863526000059
  • Figure 0007863526000060
    Figure 0007863526000060
Patent Text Reader

Abstract

To provide potent GLP-1 agonists with reduced adverse effect and improved duration of action.SOLUTION: Provided is a novel Glucagon like Peptide- 1 (GLP-1) analogs having an amino acid sequence with Leu or Ile at the C-terminal, the GLP-1 analogs having specific sequences and modifications, requiring no frequent subcutaneous administration, also being suitable for oral administration, having a stable and long duration of action, and having a potent action of GLP-1 agonist.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art